extens
geograph
distribut
medic
import
tickborn
viral
diseas
close
approxim
known
global
distribut
hyalomma
spp
tick
human
be
becom
infect
tick
bite
crush
infect
tick
contact
patient
cchf
acut
phase
infect
contact
blood
tissu
viraem
livestock
clinic
featur
commonli
show
dramat
progress
characteris
haemorrhag
myalgia
fever
level
liver
enzym
creatinin
phosphokinas
lactat
dehydrogenas
rais
bleed
marker
prolong
infect
endothelium
major
pathogen
role
besid
direct
infect
endothelium
indirect
damag
viral
factor
virusmedi
hostderiv
solubl
factor
caus
endotheli
activ
dysfunct
thought
occur
diagnosi
enzymelink
immunoassay
realtim
revers
transcriptas
pcr
use
earli
diagnosi
critic
patient
therapi
prevent
potenti
nosocomi
infect
support
therapi
essenti
part
case
manag
recent
studi
suggest
ribavirin
eff
ectiv
cchf
although
defi
nitiv
studi
avail
healthcar
worker
seriou
risk
infect
particularli
care
patient
haemorrhag
nose
mouth
gum
vagina
inject
site
simpl
barrier
precaut
report
eff
ectiv
crimeancongo
haemorrhag
fever
cchf
fatal
viral
infect
describ
part
africa
asia
eastern
europ
middl
east
viru
belong
genu
nairoviru
bunyavirida
famili
caus
sever
diseas
human
be
report
mortal
rate
geograph
rang
cchf
viru
extens
one
among
medic
import
tickborn
virus
fi
gure
human
be
becom
infect
tick
bite
contact
patient
cchf
acut
phase
infect
contact
blood
tissu
viraem
livestock
clinic
featur
show
common
dramat
progress
characteris
haemorrhag
myalgia
fever
diff
erenc
among
diff
erent
region
suggest
well
studi
treatment
ribavirin
yet
approv
mani
countri
howev
report
indic
drug
may
benefi
cial
widespread
geograph
distribut
cchf
viru
abil
produc
sever
human
diseas
high
mortal
rate
fear
intent
use
bioterror
agent
make
viru
import
human
pathogen
moreov
ecolog
complex
vectorborn
diseas
therapeut
controversi
humantohuman
transmiss
zoonot
infect
make
cchf
interest
topic
research
substanti
increas
report
cchf
viru
past
year
review
publish
work
cchf
emphasi
recent
outbreak
turkey
cchf
virusinfect
case
fi
rst
report
turkey
although
epidem
report
neighbour
countri
sinc
case
report
turkish
ministri
health
case
die
centuri
haemorrhag
syndrom
describ
present
day
tajikistan
sign
presenc
blood
urin
rectum
gum
vomitu
sputum
abdomin
caviti
arthropod
caus
diseas
said
tough
small
relat
lous
tick
normal
parasitis
black
bird
modern
era
crimean
haemorrhag
fever
fi
rst
describ
clinic
entiti
soviet
militari
personnel
infect
assist
peasant
crimea
wake
world
war
viru
isol
blood
tissu
patient
use
intracerebr
inocul
newborn
white
mice
viru
respons
crimean
haemorrhag
fever
later
shown
review
antigen
indistinguish
congo
viru
isol
febril
patient
belgian
congo
present
day
democrat
republ
congo
common
antigen
structur
among
eurasian
crimean
haemorrhag
fever
strain
asian
african
strain
congo
viru
led
viru
call
crimean
haemorrhag
fevercongo
viru
crimeancongo
haemorrhag
fever
viru
geograph
rang
cchf
viru
extens
among
tickborn
virus
aff
ect
human
health
second
widespread
medic
import
arbovirus
dengu
virus
fi
gure
histori
report
outbreak
summaris
tabl
case
report
former
soviet
union
crimea
astrakhan
rostov
uzbekistan
kazakhstan
tajikistan
bulgaria
well
viru
circul
part
africa
democrat
republ
congo
uganda
outbreak
china
case
fatal
rate
note
present
detail
initi
recognit
haemorrhag
case
africa
occur
result
seri
indepth
studi
south
africa
report
addit
outbreak
congo
mauritania
burkina
faso
tanzania
seneg
substanti
number
case
also
report
middl
eastern
countri
iraq
unit
arab
emir
uae
saudi
arabia
oman
pakistan
china
new
outbreak
report
pakistan
iran
seneg
albania
yugoslavia
bulgaria
turkey
kenya
mauritania
serolog
evid
cchf
viru
report
greec
india
egypt
portug
hungari
franc
benin
although
viru
isol
greec
report
human
case
greek
laboratori
infect
cchf
viru
endem
balkan
includ
bulgaria
former
yugoslavia
albania
interest
strain
caus
laboratoryrel
infect
greec
exceedingli
mild
possibl
refl
ect
chanc
variat
howev
viru
greatest
phylogenet
diff
erenc
cchf
virus
greec
separ
bulgaria
mountain
approxim
high
microbiolog
life
cycl
viru
cchf
member
nairoviru
genu
famili
bunyavirida
genera
within
famili
includ
orthobunyaviru
hantaviru
phleboviru
tospoviru
nairoviru
genu
includ
describ
virus
divid
seven
diff
erent
serogroup
import
group
cchf
group
includ
cchf
viru
hazara
viru
nairobi
sheep
diseas
group
includ
nairobi
sheep
diseas
dugb
virus
cchf
viru
dugb
viru
nairobi
sheep
diseas
viru
three
member
nairoviru
genu
known
caus
diseas
among
human
be
bunyavirus
envelop
particl
singlestrand
rna
genom
neg
polar
fi
gure
three
genom
segment
encod
four
structur
proteinsth
rnadepend
rna
polymeras
l
protein
encod
larg
l
segment
glycoprotein
gn
gc
previous
refer
encod
medium
segment
nucleocapsid
protein
n
encod
small
segment
emerg
data
viral
replic
show
great
potenti
develop
new
drug
viral
glycoprotein
respons
recognit
receptor
site
suscept
cell
follow
attach
virus
internalis
endocytosi
replic
occur
cytoplasm
virion
matur
bud
endoplasm
reticulum
cytoplasm
vesicl
golgi
region
bunyavirus
known
bud
golgi
membran
bud
site
seem
defi
ned
retent
glycoprotein
gn
gc
particular
site
gn
localis
golgi
compart
wherea
gc
found
endoplasm
reticulum
recent
express
strategi
biosynthesi
cchf
viral
glycoprotein
studi
detail
includ
identifi
cation
precursor
cleavag
site
determin
exact
amino
termini
two
major
cleavag
product
gn
gc
subtilas
identifi
ed
cellular
proteas
respons
process
step
gener
amino
terminu
matur
gn
recent
studi
l
rna
genom
segment
predict
encod
l
polymeras
protein
cchf
viru
demonstr
approxim
twice
size
found
virus
bunyaviru
genera
region
contain
ovarian
tumourlik
cystein
proteas
helicas
domain
identifi
ed
l
segment
cchf
dugb
virus
suggest
autoproteolyt
cleavag
process
nairoviru
l
protein
phylogenet
studi
worldwid
divers
viru
fi
rst
name
cchf
viru
antigen
structur
virus
variou
geograph
region
thought
indistinguish
howev
develop
nucleic
acid
sequenc
analysi
techniqu
reveal
extens
genet
divers
nucleic
acid
sequenc
analys
base
segment
genom
although
recent
studi
done
rna
segment
accord
studi
eight
genet
distinct
clade
low
genet
diverg
european
strain
group
togeth
except
greek
strain
strain
southeast
russia
close
relat
european
strain
turkish
cchf
viru
isol
recent
outbreak
cluster
close
cchf
viral
strain
southwest
russia
kosovo
bootstrap
analysi
show
clade
contain
russian
balkan
turkish
cchf
virus
well
support
virus
clearli
distinct
viru
clade
includ
clade
contain
viru
detect
cchf
outbreak
neighbour
iran
strain
isol
rhipicephalu
bursa
tick
greec
diff
er
european
strain
form
independ
clade
genet
diff
erenc
may
attribut
diff
erent
speci
tick
vector
genet
isol
adjac
mountain
rang
third
clade
form
strain
central
asianam
kazahkstan
tajikistan
uzbekistan
china
close
relat
phylogenet
analysi
segment
show
chines
cchf
viru
isol
cluster
three
group
one
close
relat
nigerian
isol
isol
iran
madagascar
pakistan
found
close
relat
form
fourth
clade
partial
ssegment
nucleotid
sequenc
show
iranian
viral
isol
cluster
along
strain
pakistan
madagascar
one
distinct
lineag
phylogenet
analysi
also
demonstr
iranian
isol
examin
studi
cchf
viru
strain
cluster
diff
erent
genet
group
indic
least
two
genet
lineag
cchf
viru
could
cocircul
iran
second
group
strain
iran
close
relat
strain
seneg
mauritania
togeth
form
fi
fth
clade
final
three
distinct
clade
africa
fi
rst
strain
seneg
mauritania
south
africa
second
strain
nigeria
central
african
republ
third
strain
uganda
cchf
viru
circul
enzoot
tickvertebratetick
cycl
evid
viru
caus
diseas
anim
cchf
viral
infect
commonli
demonstr
among
smaller
wildlif
specieseg
hare
hedgehogsthat
act
host
immatur
stage
tick
vector
antibodi
cchf
viru
detect
sera
hors
donkey
goat
cattl
sheep
pig
variou
region
europ
asia
africa
must
born
review
mind
antibodi
studi
particularli
preval
low
meaning
obtain
actual
viru
isol
although
groundfeed
bird
shown
detect
viraemia
bird
may
role
transport
cchf
virusinfect
tick
diff
erent
countri
cchf
virus
transmit
hyalomma
genu
tick
particularli
hyalomma
marginatum
marginatum
cchf
viru
isol
adult
hyalomma
genu
tick
viral
isol
also
obtain
fi
eldcollect
egg
unf
immatur
stage
h
marginatum
provid
evid
transovari
ie
infect
mother
egg
stage
transstadi
ie
larva
nymph
adult
transmiss
known
occurr
cchf
europ
asia
africa
coincid
global
distribut
hyalomma
tick
h
marginatum
marginatum
known
mediterranean
hyalomma
may
main
vector
cchf
viru
europ
cchf
viru
also
isol
hyalomma
anatolicum
anatolicum
hyalomma
spp
isol
tick
generaeg
rhipicephalu
ornithodoro
boophilu
dermacentor
ixod
spp
may
local
import
transmit
viru
laboratori
viral
isol
alon
incrimin
vector
without
addit
laboratori
epidemiolog
studi
chang
climat
condit
suggest
one
factor
facilit
reproduct
tick
popul
consequ
increas
incid
tickborn
infecti
diseas
northern
hemispher
h
marginatum
marginatum
usual
activ
increas
temperatur
spring
particularli
april
may
immatur
stage
activ
summer
may
septemb
exampl
ukrainian
stepp
fi
rst
adult
hyalomma
appear
averag
daili
temperatur
reach
april
april
follow
year
tick
densiti
reduc
sever
winter
astrakhan
oblast
feder
republ
russia
consequ
number
case
cchf
drastic
reduc
number
day
temperatur
april
daili
mean
temperatur
april
region
turkey
aff
ect
recent
outbreak
report
increas
year
outbreak
howev
climat
chang
necessarili
caus
mark
increas
incid
varieti
tickborn
diseas
mani
part
europ
past
two
decad
gener
cchf
outbreak
develop
background
favour
climat
factor
environment
chang
benefi
cial
surviv
larg
number
hyalomma
spp
tick
host
immatur
adult
stage
former
soviet
union
environment
chang
includ
wartim
neglect
agricultur
land
introduct
suscept
militari
personnel
new
settler
infect
area
wide
scale
collectivis
agricultur
chang
pastur
pattern
convert
fl
oodplain
farmland
fl
ood
control
world
war
occup
crimea
normal
agricultur
activ
disrupt
common
sport
hunt
european
hare
abandon
soviet
troop
reoccupi
hilli
crimean
stepp
hare
becom
excess
abund
neglect
pastur
overgrown
weed
fi
rst
outbreak
modern
era
document
interestingli
similar
explan
suggest
outbreak
turkey
fi
eld
aff
ect
region
abandon
hunt
pastur
terrorist
activ
region
period
number
small
mammal
eg
hare
wild
anim
eg
boar
increas
fi
eld
becam
avail
hunt
pastur
cattl
sheep
expos
viruscarri
tick
potenti
role
migratori
bird
movement
livestock
carri
tick
spread
viru
distant
geograph
area
studi
bird
migrat
balkan
suggest
caus
outbreak
turkey
howev
precis
data
cchf
viru
bird
birdparasitis
tick
epidemiolog
cchf
case
distribut
mainli
among
activ
work
age
group
expos
tick
popul
major
atrisk
group
farmer
live
endem
area
aff
ect
case
deal
agricultur
andor
anim
husbandri
almost
case
recent
outbreak
turkey
farmer
work
larg
domest
anim
also
atrisk
group
acquisit
viru
usual
take
place
slaughter
anim
viraem
blood
subclin
infect
anim
like
sourc
infect
exposur
tick
process
also
like
least
case
meat
risk
viru
inactiv
postslaught
acidifi
cation
tissu
would
surviv
cook
case
hike
camp
rural
activ
also
risk
factor
tick
exposur
gender
distribut
vari
countri
depend
particip
women
agricultur
work
outbreak
recent
report
south
africa
heavili
tickinfest
ostrich
slaughter
infect
report
acquir
either
contact
ostrich
blood
inadvert
crush
infect
tick
skin
ostrich
although
antibodi
detect
among
bird
outbreak
ostrich
experiment
infect
viraemia
observ
day
infect
publichealth
measur
studi
suggest
bird
kept
free
tick
day
slaughter
healthcar
worker
second
aff
ect
group
hospit
healthcar
worker
seriou
risk
transmiss
cchf
infect
care
patient
haemorrhag
nose
mouth
gum
vagina
inject
site
transmiss
cchf
infect
death
among
healthcar
worker
report
parallel
outbreak
gener
popul
tabl
one
hospit
outbreak
report
healthcar
worker
expos
infect
blood
needlestick
injuri
develop
diseas
cchf
viru
repeatedli
caus
nosocomi
outbreak
high
mortal
percutan
exposur
present
highest
risk
transmiss
danger
set
acquir
cchf
viru
intervent
gastrointestin
bleed
emerg
oper
patient
yet
diagnos
cchf
gener
patient
diagnos
oper
injuri
oper
team
oper
usual
underreport
airborn
acquisit
infect
suspect
sever
case
russia
document
horizont
transmiss
mother
child
also
report
human
be
known
host
cchf
viru
diseas
manifest
one
russian
studi
probabl
develop
cchf
peopl
infect
found
one
everi
fi
infect
peopl
develop
cchf
typic
cours
cchf
infect
four
distinct
phase
incub
prehaemorrhag
haemorrhag
convalesc
period
fi
gure
incub
period
follow
tick
bite
usual
daysbut
diffi
cult
obtain
precis
data
incub
period
could
diff
er
depend
sever
factor
includ
viral
dose
rout
exposureeg
could
shorter
bloodborn
transmiss
south
africa
time
onset
diseas
exposur
tick
bite
day
day
follow
exposur
blood
tissu
livestock
day
exposur
blood
infect
human
be
mean
durat
diseas
cours
present
hospit
report
day
turkey
day
uae
prehaemorrhag
period
characteris
sudden
onset
fever
headach
myalgia
dizzi
averag
fever
persist
day
addit
symptom
diarrhoea
nausea
vomit
also
seen
case
hyperaemia
face
neck
chest
congest
sclera
conjunct
commonli
note
prehaemorrhag
period
last
averag
day
rang
day
haemorrhag
period
short
usual
day
develop
rapidli
usual
begin
third
fi
fth
day
diseas
relat
temperatur
feverish
patient
onset
haemorrhag
haemorrhag
manifest
rang
petechia
larg
haematoma
appear
mucou
membran
skin
fi
gure
bleed
site
includ
vagina
gingiv
bleed
cerebr
haemorrhag
report
common
bleed
site
nose
gastrointestin
system
haematemesi
melena
intraabdomin
uteru
menometrorrhagia
urinari
tract
haematuria
review
respiratori
tract
haemoptysi
atyp
present
bleed
also
seen
exampl
one
patient
stubborn
abdomin
pain
acut
append
suspect
haemorrhag
bleed
intern
extern
obliqu
muscl
caecum
detect
patholog
appendix
hepatomegali
splenomegali
report
occur
onethird
patient
turkey
hepatomegali
detect
case
two
studi
report
splenomegali
frequenc
convalesc
period
begin
survivor
day
onset
ill
patient
remain
hospit
around
day
convalesc
period
labil
puls
tachycardia
temporari
complet
loss
hair
polyneur
diffi
culti
breath
xerostomia
poor
vision
loss
hear
loss
memori
report
although
none
fi
nding
note
recent
outbreak
turkey
although
cardiovascular
changeseg
bradycardia
low
blood
pressurewer
report
earlier
review
emphasis
recent
hepatoren
insuffi
cienci
report
south
africa
turkey
known
relaps
infect
biphas
cours
diseasea
note
publish
work
former
soviet
union
observ
turkey
thrombocytopenia
appear
consist
featur
cchf
infect
patient
leucopenia
rais
level
aspart
aminotransferas
alanin
aminotransferas
lactat
dehydrogenas
creatinin
phosphokinas
coagul
test
prothrombin
time
activ
partial
thromboplastin
time
prolong
level
fi
brinogen
might
decreas
fi
brin
degrad
product
could
increas
laboratori
test
includ
complet
blood
count
biochem
test
return
normal
level
within
approxim
day
among
surviv
patient
fi
gure
swanepoel
colleagu
describ
clinic
laboratori
criteria
could
measur
earli
cours
diseas
fi
rst
day
predict
fatal
outcom
patient
fi
nding
white
blood
cell
count
cell
per
l
platelet
count
per
l
aspart
aminotransferas
level
ul
alanin
aminotransferas
ul
activ
partial
thromboplastin
time
second
fi
brinogen
level
mgdl
case
seri
confi
rmed
level
aspart
aminotransferas
alanin
aminotransferas
signifi
cantli
higher
among
sever
case
p
studi
turkey
higher
aspart
aminotransferas
alanin
aminotransferas
level
iul
respect
found
higher
sensit
sever
case
leucocytosi
observ
one
four
fatal
patient
keep
prognost
import
abnorm
activ
partial
thromboplastin
time
fi
brinogen
note
swanepoel
cowork
patient
fatal
outcom
seri
overt
dissemin
intravascular
coagul
accord
criteria
defi
ned
intern
societi
thrombosi
haemostasi
haematemesi
melena
somnol
signifi
cantli
common
among
patient
fatal
outcom
respect
particular
import
fact
fatal
case
littl
evid
antibodi
respons
pathogenesi
cchf
well
describ
common
pathogen
featur
haemorrhag
fever
virus
abil
disabl
host
immun
respons
attack
manipul
cell
initi
antivir
respons
damag
characteris
mark
replic
viru
togeth
dysregul
vascular
system
lymphoid
organ
infect
endothelium
import
role
cchf
pathogenesi
endothelium
target
two
waysindirectli
viral
factor
virusmedi
review
hostderiv
solubl
factor
caus
endotheli
activ
dysfunct
andor
directli
viru
infect
replic
endotheli
cell
endotheli
damag
contribut
haemostat
failur
stimul
platelet
aggreg
degranul
consequ
activ
intrins
coagul
cascad
inde
fatal
cchf
case
grossli
abnorm
indic
coagul
system
function
earli
stage
ill
dissemin
intravascular
coagul
note
earli
promiment
featur
diseas
process
one
studi
turkey
reactiv
haemophagocytosi
detect
seven
patient
suggest
haemophagocytosi
could
role
cytopenia
observ
cchf
infect
haemophagocyt
lymphohistiocytosi
attribut
excess
activ
monocyt
high
level
cytokineseg
interferon
gamma
tumour
necrosi
factor
alpha
interleukin
interleukin
fi
nding
provid
indirect
evid
particip
cytokin
aspect
cchf
pathogenesi
one
studi
cchf
patient
level
interleukin
interleukin
tumour
necrosi
factor
alpha
higher
among
patient
subsequ
die
compar
surviv
dissemin
intravascular
coagul
score
higher
among
fatal
case
correl
posit
interleukin
tumour
necrosi
factor
alpha
level
neg
interleukin
level
earli
diagnosi
critic
patient
surviv
prevent
potenti
nosocomi
infect
transmiss
commun
suspect
case
evalu
manag
care
plan
includ
support
care
particularli
haematolog
support
panel
diff
erenti
diagnosi
list
diff
er
accord
geograph
locat
includ
bacteri
viral
noninfecti
caus
tabl
viru
isol
studi
done
highcontain
laboratori
gener
recommend
biosafeti
level
four
isol
cell
cultur
simpler
rapid
less
sensit
tradit
method
intracrani
inocul
sampl
newborn
mice
viru
isol
use
cell
line
includ
vero
viru
isol
achiev
day
cell
cultur
lack
sensit
usual
allow
detect
rel
high
viraemia
encount
fi
rst
day
ill
viru
may
produc
littl
cytopath
eff
ect
identifi
ed
immunofl
uoresc
assay
test
specifi
c
monoclon
antibodi
although
revers
transcriptas
pcr
extrem
use
rapid
diagnosi
viru
isol
yield
viru
subject
biolog
sequenc
studi
antigen
captur
elisa
also
shown
use
spite
rel
lack
sensit
process
detect
sever
case
would
requir
antivir
therapi
could
candid
trial
antivir
drug
relaps
occur
diseas
therefor
need
follow
case
healthcar
worker
expos
viru
follow
complet
blood
count
biochem
test
day
revers
transcriptas
pcr
method
choic
rapid
laboratori
diagnosi
cchf
viru
infect
method
highli
specifi
c
sensit
rapid
improv
develop
autom
realtim
assay
lower
contamin
rate
higher
sensit
specifi
citi
rapid
convent
revers
transcriptas
pcr
igm
igg
antibodi
detect
elisa
immunofl
uoresc
assay
day
onset
diseas
review
twice
day
potenti
bleed
foci
consid
conserv
measur
takeneg
use
histamin
receptor
blocker
peptic
ulcer
patient
avoid
intramuscular
inject
use
aspirin
drug
action
coagul
system
fluid
electrolyt
balanc
also
monitor
meticul
ribavirin
recommend
antivir
agent
infect
patient
although
mechan
action
clear
one
invitro
studi
ribavirin
shown
inhibit
viral
activ
cchf
viral
strain
appear
sensit
other
experiment
studi
done
mice
ribavirin
treatment
substanti
reduc
infant
mous
mortal
extend
mean
time
death
note
evid
randomis
clinic
trial
use
ribavirin
treat
human
cchfit
eff
ectiv
describ
observ
studi
mild
case
need
treat
ribavirin
case
manag
sever
case
defi
ned
treat
sever
case
turkey
defi
ned
accord
revis
form
swanepoel
criteria
oral
intraven
form
ribavirin
avail
mani
countri
patient
treat
day
mgkg
initi
load
dose
mgkg
everi
hour
day
mgkg
everi
hour
day
haemolyt
anaemia
hypocalcaemia
hypomagnesaemia
report
patient
receiv
ribavirin
treat
sever
acut
respiratori
syndrom
howev
advers
event
relat
ribavirin
therapi
note
among
cchf
patient
turkey
use
ribavirin
contraind
pregnant
women
one
studi
suggest
treatment
use
passiv
immunotherapi
transfer
plasma
convalesc
survivor
infect
patient
howev
studi
control
group
limit
seven
patient
paraga
colleagu
screen
drug
potenti
activ
cchf
viru
found
ribavirin
inhibit
replic
cchf
viru
ribamidin
antivir
activ
eightfold
less
ribavirin
three
drug
selenazofurin
tiazofurin
signifi
cant
antivir
activ
newli
identifi
ed
molecul
known
mxa
member
interferoninduc
gtpase
belong
dynamin
superfamili
prevent
replic
cchf
viral
rna
present
intracellularli
inhibit
product
new
infecti
viru
particl
interact
compon
nucleocapsid
peopl
live
endem
area
use
person
protect
measur
includ
avoid
area
tick
vector
abund
particularli
activ
regular
examin
cloth
skin
tick
remov
use
repel
peopl
expos
potenti
viraem
anim
blood
take
practic
measur
protect
includ
use
repel
skin
cloth
wear
glove
protect
cloth
prevent
skin
contact
infect
tissu
blood
recommend
safeti
measur
healthcar
worker
includ
barrier
nurs
isol
use
glove
gown
faceshield
goggl
side
shield
contact
patient
soil
environment
surfac
simpl
barrier
precaut
report
eff
ectiv
strict
adher
univers
barrier
precaut
hospit
turkey
recent
outbreak
meant
antibodi
cchf
viru
found
atrisk
healthcar
worker
serolog
screen
outbreak
recent
studi
prophylact
ribavirin
administ
healthcar
worker
needlestick
injuri
healthcar
worker
subsequ
develop
cchf
administr
oral
ribavirin
prophylaxi
ere
anyon
high
risk
infect
directli
expos
blood
cchf
patient
contact
needlestick
injuri
howev
rigor
daili
followup
individu
check
white
blood
cell
count
biochem
test
least
day
exposur
suffi
cient
ribavirin
administ
fever
develop
immunis
programm
introduc
medic
worker
militari
personnel
cchfendem
area
vaccin
consist
mous
brain
prepar
inactiv
chloroform
heat
adsorb
aluminium
hydroxid
propos
vaccin
help
reduc
number
case
case
fatal
rate
area
vaccin
also
given
human
volunt
bulgaria
report
elicit
antibodi
product
individu
howev
experi
vaccin
cchf
viru
limit
limit
durat
confi
ned
locat
vaccin
would
suitabl
use
mani
countri
method
prepar
dynam
enzoot
environ
transmiss
cycl
cchf
viru
need
detail
role
climat
factor
reservoir
host
vector
describ
studi
need
multidisciplinari
team
work
includ
entomologist
microbiologist
epidemiologist
veterinarian
data
review
identifi
ed
search
pubm
googl
refer
relev
articl
use
search
term
crimean
congo
haemorrhag
fever
viral
haemorrhag
fever
ribavirin
date
limit
set
abstract
nonenglish
languag
paper
includ
clinician
new
data
viral
replic
er
substanti
potenti
develop
new
drug
studi
pathogenesi
viral
haemorrhag
fever
shed
light
mechan
dissemin
intravascular
coagul
probabl
bacteri
sepsi
understand
new
mechan
cchf
viral
infect
viral
haemorrhag
fever
assist
develop
new
therapeut
molecul
agent
use
treat
dissemin
intravascular
coagulationeg
heparin
coagul
blockerscould
tri
control
clinic
cours
cchf
confl
ict
interest
declar
confl
ict
interest
